N-(4-acetoxyphenyl)piperazine | 144881-49-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: N-(4-acetoxyphenyl)piperazine
• 英文别名: 1-(4-acetoxyphenyl)piperazine；(4-piperazin-1-ylphenyl) acetate
• CAS: 144881-49-2
• 化学式: C₁₂H₁₆N₂O₂
• 分子量: 220.271
• InChiKey: OKKCWNMOWJYMMC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(4-acetoxyphenyl)piperazine 以 甲醇 、 乙醇 为溶剂， 反应 36.0h， 生成 [4-[4-[(2-Amino-4,5-dihydro-1,3-oxazol-5-yl)methyl]piperazin-1-yl]phenyl] acetate
  参考文献：
  名称：

  Synthesis and antidepressant activity of 5-(1-aryl-4-piperazino)methyl-2-amino-2-oxazolines

  摘要：

  The synthesis of 20 5-(1-aryl-4-piperazino)methyl-2-amino-2-oxazolines is described. Antidepressant activity was observed in mice using classical screening tests. Structure-activity relationships were studied and correlated with the nature of the aromatic substituent. Preliminary lipophilic and electronic properties of one lead compound (COR 3224) have been described.

  DOI：

  10.1016/0223-5234(92)90177-3

文献信息

• Piperazine derivatives and methods for the preparation thereof and
  申请人：Samjin Pharmaceuticazl Co., Ltd.

  公开号：US05780472A1

  公开（公告）日：1998-07-14

  The present invention relates to novel compound of the general formula(I) and acid addition salt thereof. ##STR1## wherein R.sub.1 and R.sub.2 are independently hydrogen, C.sub.1 -C.sub.8 alkyl or optionally substituted C.sub.3 -C.sub.6 membered cycloalkyl containing C.sub.3 -C.sub.8 ; R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are independently hydrogen, halogen, hydroxy, nitro, C.sub.1 -C.sub.4 lower ester, C.sub.1 -C.sub.4 lower alkyl, C.sub.1 -C.sub.4 lower alkoxy, aryl, arylalkoxy or unsaturated amine; l is an integer of 0-7; m and n are independently an integer of 0-1; W is carbon or nitrogen; X is oxygen, sulfur, optionally substituted imine; Y is nitrogen or oxygen; and Z is hydrogen, C.sub.1 -C.sub.8 alkoxy, aryloxy, C.sub.1 -C.sub.4 alkylamine, cycloamine containing N.sub.1 -N.sub.5 or oxo group. The present compounds of the above formula (I) has no only strong antimumor activities but lower toxicities, and accordingly are expected as novel antitumor agents.

  本发明涉及一般式(I)的新化合物及其酸盐。其中R.sub.1和R.sub.2独立地是氢、C.sub.1-C.sub.8烷基或可选择取代的含有C.sub.3-C.sub.6的C.sub.3-C.sub.8环烷基；R.sub.3、R.sub.4、R.sub.5、R.sub.6和R.sub.7独立地是氢、卤素、羟基、硝基、C.sub.1-C.sub.4较低酯基、C.sub.1-C.sub.4较低烷基、C.sub.1-C.sub.4较低烷氧基、芳基、芳基氧基或不饱和胺基；l是0-7的整数；m和n独立地是0-1的整数；W是碳或氮；X是氧、硫、可选择取代的亚胺；Y是氮或氧；Z是氢、C.sub.1-C.sub.8烷氧基、芳氧基、C.sub.1-C.sub.4烷基胺、含N.sub.1-N.sub.5的环胺或氧代基。上述一般式(I)的化合物具有强抗肿瘤活性和较低毒性，因此被期望作为新型抗肿瘤药物。
• [EN] IMIDAZOLE DERIVATIVES<br/>[FR] DÉRIVÉS D'IMIDAZOLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2012064569A1

  公开（公告）日：2012-05-18

  Described herein are compounds of formula (I), formula la or formula lb The compounds of formula I, formula la or formula lb act as DGATl inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

  本文描述的是式(I)、式la或式lb的化合物。式(I)、式la或式lb的化合物作为DGATl抑制剂，在预防、治疗或作为治疗高脂血症、糖尿病和肥胖症的药物中可能有用。
• SAR of the arylpiperazine moiety of obeline somatostatin sst1 receptor antagonists
  作者：Konstanze Hurth、Albert Enz、Philipp Floersheim、Conrad Gentsch、Daniel Hoyer、Daniel Langenegger、Peter Neumann、Paul Pfäffli、Dieter Sorg、Robert Swoboda、Annick Vassout、Thomas Troxler

  DOI：10.1016/j.bmcl.2007.04.078

  日期：2007.7

  The SAR of over 50 derivatives of octahydrobenzo[g]quinoline (obeline)-type somatostatin sst, receptor antagonist 1 is presented, focusing on the modification of its arylpiperazine moiety. sst(1) affinities in this series cover a range of five orders of magnitude with the best derivatives displaying subnanomolar sst, affinities and > 10,000-fold selectivities over the sst, receptor subtype as well as promising pharmacokinetic properties. (C) 2007 Elsevier Ltd. All rights reserved.
• US5780472A
  申请人：——

  公开号：US5780472A

  公开（公告）日：1998-07-14
• [EN] NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME<br/>[FR] NOUVEAUX DERIVES PIPERAZINES, LEURS PROCEDES DE PREPARATION, ET COMPOSITIONS LES CONTENANT
  申请人：SAMJIN PHARMACEUTICAL CO., LTD.

  公开号：WO1996021648A1

  公开（公告）日：1996-07-18

  (EN) The present invention relates to novel compound of general formula (I) and acid addition salt thereof, wherein R1 and R2 are independently hydrogen, C1-C8 alkyl or optionally substituted C3-C6 membered cycloalkyl containing C3-C8; R3, R4, R5, R6 and R7 are independently hydrogen, halogen, hydroxy, nitro, C1-C4 lower ester, C1-C4 lower alkyl, C1-C4 lower alkoxy, aryl, arylalkoxy or unsaturated amine; 1 is an integer of 0-7; m and n are independently an integer of 0-1; W is carbon or nitrogen; X is oxygen, sulfur, optionally substituted imine; Y is nitrogen or oxygen; and Z is hydrogen, C1-C8 alkoxy, aryloxy, C1-C4 alkylamine, cycloamine containing N1-N5 or oxo group. The present compounds of the above formula (I) have not only strong antitumor activities but lower toxicities, and accordingly are expected as novel antitumor agents.(FR) Nouveau composé répondant à la formule générale (I), et son sel d'addition d'acide, dans laquelle R1 et R2, indépendamment l'un de l'autre, représentent hydrogène, alkyle C1-8 ou cycloalkyle C3-6 éventuellement substitué renfermant C3-8; R3, R4, R5, R6 et R7, indépendamment les uns des autres, représentent hydrogène, halogène, hydroxy, nitro, ester inférieur C1-4, alkyle inférieur C1-4, alcoxy inférieur C1-4, aryle, arylalcoxy ou amine insaturée; 1 est un nombre entier compris entre 0 et 7; m et n, indépendamment l'un de l'autre, sont 0 ou 1; W représente carbone ou azote; X représente oxygène, soufre ou imine éventuellement substituée; Y représente azote ou oxygène; et Z représente hydrogène, alcoxy C1-8, aryloxy, alkylamine C1-4, cycloamine renfermant N1-5 ou un groupe oxo. Les composés répondant à la formule (I) présentent non seulement de fortes activités antitumorales mais également des toxicités réduites, et ils sont de ce fait utilisables comme nouveaux agents antitumoraux.